Ellen J. Hoekman
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Ellen J. Hoekman has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
Carina G. J. M. Hilders
Department of Gynecology, Reinier de Graaf Hospital, Delft, the Netherlands
2 shared publicationsCornelis D. de Kroon
Department of Gynecology and IVF, Leiden University Medical Center, Leiden, The Netherlands
2 shared publicationsFrank W. Jansen
Leiden University Medical Center, Department of Gynecology, Leiden, South Holland, the Netherlands
2 shared publicationsLeoni A. Louwe
Department of Gynecology and IVF, Leiden University Medical Center, Leiden, The Netherlands
2 shared publicationsAlexander A. W. Peters
Department of gynecology, Leiden University Medical Center, P/O Box 9600, 2300RC, Leiden, The Netherlands
1 shared publicationC. A. M. Jansen
IVF Dept., Reinier de Graaf Group, P/O Box 998, 2275 CX Voorburg, The Netherlands
1 shared publication
Latest Publications
- Open Access
- 8 October 2019
- Published by Wiley in Acta Obstetricia et Gynecologica Scandinavica
- Vol. 99 (2) , 213-221
Ovarian tissue cryopreservation: Low usage rates and high live‐birth rate after transplantation
Introduction: The likelihood of survival after cancer treatment among young women with cancer has increased considerably, quality of life after treatment has drawn more attention. However, in young fertile women, fertility preservation is an important issue with regard to quality of life. One of the options of fertility preservation is ovarian tissue cryopreservation. The purpose of this follow‐up study is to present our clinical experiences and evaluate the long‐term follow up of ovarian cryopreservation to improve future patient selection.Material and methods: From July 2002 to December 2015 at the Leiden University Hospital, the Netherlands, 69 young women underwent ovarian tissue cryopreservation when they were at risk of iatrogenic premature ovarian insufficiency. Follow‐up data with regard to ovarian function were obtained until October 2018, from medical records and questionnaires.Results: Of the 69 women in whom ovarian tissue cryopreservation was performed, 12 died (15.9%), 57 were approached to participate, of which 6 were lost to follow up. The indications for ovarian tissue cryopreservation were malignant (81.1%) and benign (18.9%) diseases in which gonadotoxic treatment was scheduled. In total, twenty women (39.2%) are known to have premature ovarian insufficiency due to gonadotoxic treatment. Fifteen women conceived spontaneously, and delivered 25 babies. In this cohort, the usage rate of autotransplantation is 8.7% (7/69). In total, nine autotransplantations of cryopreserved ovarian tissue were performed in seven patients (of which 1 ovarian tissue cryopreservation was performed in another hospital) after which 6 babies were born to four women, giving a live‐birth rate of 57%.Conclusions: Ovarian tissue cryopreservation followed by autotransplantation is an effective method to restore fertility (live‐birth rate of 57%). The usage rate of 8.7% (6/69) indicates that more knowledge about the risk of premature ovarian insufficiency after gonadotoxic treatment is needed to be able to offer ovarian tissue cryopreservation more selectively.
- 8 October 2019
- Published by Wiley in Acta Obstetricia et Gynecologica Scandinavica
- Vol. 99 (2) , 213-221
Open AccessOvarian tissue cryopreservation: Low usage rates and high live‐birth rate after transplantation
Introduction: The likelihood of survival after cancer treatment among young women with cancer has increased considerably, quality of life after treatment has drawn more attention. However, in young fertile women, fertility preservation is an important issue with regard to quality of life. One of the options of fertility preservation is ovarian tissue cryopreservation. The purpose of this follow‐up study is to present our clinical experiences and evaluate the long‐term follow up of ovarian cryopreservation to improve future patient selection.Material and methods: From July 2002 to December 2015 at the Leiden University Hospital, the Netherlands, 69 young women underwent ovarian tissue cryopreservation when they were at risk of iatrogenic premature ovarian insufficiency. Follow‐up data with regard to ovarian function were obtained until October 2018, from medical records and questionnaires.Results: Of the 69 women in whom ovarian tissue cryopreservation was performed, 12 died (15.9%), 57 were approached to participate, of which 6 were lost to follow up. The indications for ovarian tissue cryopreservation were malignant (81.1%) and benign (18.9%) diseases in which gonadotoxic treatment was scheduled. In total, twenty women (39.2%) are known to have premature ovarian insufficiency due to gonadotoxic treatment. Fifteen women conceived spontaneously, and delivered 25 babies. In this cohort, the usage rate of autotransplantation is 8.7% (7/69). In total, nine autotransplantations of cryopreserved ovarian tissue were performed in seven patients (of which 1 ovarian tissue cryopreservation was performed in another hospital) after which 6 babies were born to four women, giving a live‐birth rate of 57%.Conclusions: Ovarian tissue cryopreservation followed by autotransplantation is an effective method to restore fertility (live‐birth rate of 57%). The usage rate of 8.7% (6/69) indicates that more knowledge about the risk of premature ovarian insufficiency after gonadotoxic treatment is needed to be able to offer ovarian tissue cryopreservation more selectively.
- 1 August 2019
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 45 (8) , 1328-1340
Ovarian function after ovarian transposition and additional pelvic radiotherapy: A systematic review
- 1 August 2019
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 45 (8) , 1328-1340
Ovarian function after ovarian transposition and additional pelvic radiotherapy: A systematic review
- Open Access
- 14 September 2018
- Published by Springer Nature in Archives of Gynecology and Obstetrics
- Vol. 298 (5) , 1001-1007
Ovarian survival after pelvic radiation: transposition until the age of 35 years
Purpose To evaluate the effectiveness of ovarian transposition (OT) prior to radiation therapy (RT) and to evaluate the effect of age on ovarian survival (OS) after OT. Methods We performed a retrospective control study, with women (aged < 45 years) who underwent OT prior to pelvic radiation, versus women diagnosed with cervical cancer and treated with hysterectomy/trachelectomy and radiation therapy. All women were treated between 1989 and 2010. The 5 years OS rate was calculated, with a sub-analysis for age (25–30; 31–35 and 36–40 years). Ovarian failure was defined as climacteric complaints (with or without starting hormone replacement therapy) and/or laboratory measurements (FSH > 40 IU/L and/or estradiol < 100 pmol/L), or bilateral salpingo oophorectomy. Women were censored at recurrence. Results Twenty-seven women after OT and 29 controls were included. The radiation dose was 44.8 Gy (25.0–63.0 Gy) and 46.3 Gy (45.0–50.0 Gy), respectively. The 5-year ovarian survival rate was 60.3% versus controls 0% (p < 0.001 95% CI 3.48–11.50). Despite the decrease in ovarian survival after OT with increasing age, in all age groups (25–30, 30–35 and 35–40) ovarian survival after OT was significantly better compared to women without OT (p = 0.001; p = 0.004 and p = 0.000, respectively). Neither intra-vaginal radiation therapy of concomitant chemotherapy in addition to pelvic radiation significantly altered ovarian survival. Conclusions Our data shows that ovarian transposition prior to pelvic radiation is effective in women until the age of 35 years and needs to be discussed in patients aged 36–40 years.
- 14 September 2018
- Published by Springer Nature in Archives of Gynecology and Obstetrics
- Vol. 298 (5) , 1001-1007
Open AccessOvarian survival after pelvic radiation: transposition until the age of 35 years
Purpose To evaluate the effectiveness of ovarian transposition (OT) prior to radiation therapy (RT) and to evaluate the effect of age on ovarian survival (OS) after OT. Methods We performed a retrospective control study, with women (aged < 45 years) who underwent OT prior to pelvic radiation, versus women diagnosed with cervical cancer and treated with hysterectomy/trachelectomy and radiation therapy. All women were treated between 1989 and 2010. The 5 years OS rate was calculated, with a sub-analysis for age (25–30; 31–35 and 36–40 years). Ovarian failure was defined as climacteric complaints (with or without starting hormone replacement therapy) and/or laboratory measurements (FSH > 40 IU/L and/or estradiol < 100 pmol/L), or bilateral salpingo oophorectomy. Women were censored at recurrence. Results Twenty-seven women after OT and 29 controls were included. The radiation dose was 44.8 Gy (25.0–63.0 Gy) and 46.3 Gy (45.0–50.0 Gy), respectively. The 5-year ovarian survival rate was 60.3% versus controls 0% (p < 0.001 95% CI 3.48–11.50). Despite the decrease in ovarian survival after OT with increasing age, in all age groups (25–30, 30–35 and 35–40) ovarian survival after OT was significantly better compared to women without OT (p = 0.001; p = 0.004 and p = 0.000, respectively). Neither intra-vaginal radiation therapy of concomitant chemotherapy in addition to pelvic radiation significantly altered ovarian survival. Conclusions Our data shows that ovarian transposition prior to pelvic radiation is effective in women until the age of 35 years and needs to be discussed in patients aged 36–40 years.
- 1 March 2018
- Vol. 39 (2) , 147-155
LEARNING ASPECTS IN IMPLEMENTING A VITRIFICATION PROGRAM USING MOUSE BLASTOCYSTS
BACKGROUND: Oocyte vitrification is important for fertility preservation. There are debates, however, surrounding the components of the procedure itself. OBJECTIVE: before starting a vitrification program, we decided to (1) determine if blastocysts derived from previously frozen mouse embryos would be suitable to practice vitrification and (2) to analyze the factors that contributed to improving our "learning curve". MATERIALS AND METHODS: 58 expanded blastocysts cultured from commercially available frozen 1-cell mouse embryos (B6D2F1 x B6C3F1) were used. Embryos were vitrified, during 2 separate attempts, in a closed device (Cryopette) and vitrified and warmed using Ethylene Glycol-cryoprotectant vitrification kit (Vitrification Attempt 1 and 2 - VA1 and 2; Warming Attempt 1 and 2 - WA1 and 2). Differences in attempts by more focusing on the reaction of the embryo itself. The survival rate (SR) of embryos was evaluated immediately after warming (TO), then rinsed and cultured for 24 hours in an HTF-like medium (Cleavage Medium - Sage; Cooper Surgical; U.S.A.). Additional evaluations were done at 2 and 24 hours of culture (T2 and T24, respectively). RESULTS: The combined SR for both attempts were 70.6, 60.3 and 34.4% at TO, T2 and T24, respectively. Embryo loss was significantly higher in WA1 compared to WA2 (30.8 versus 10.1%; p=.05). The SR at TO after VA1 and VA2 were similar (90.9 versus 80.9%) and the SR after VA1+WA1 versus VA1+WA2 was 55.6 vs. 76.9% at T2 and 22.2 vs. 61.5% at T24, respectively (NS). CONCLUSION: Commercially frozen mouse embryos can provide essential information for initiating a Vitrification Program applicable to human embryos and oocytes. Practice is critical, particularly Warming, which can provide the confidence needed to adapt and optimize these protocols before vitrifying limited human tissues or gametes.
- 1 March 2018
- Vol. 39 (2) , 147-155
LEARNING ASPECTS IN IMPLEMENTING A VITRIFICATION PROGRAM USING MOUSE BLASTOCYSTS
BACKGROUND: Oocyte vitrification is important for fertility preservation. There are debates, however, surrounding the components of the procedure itself. OBJECTIVE: before starting a vitrification program, we decided to (1) determine if blastocysts derived from previously frozen mouse embryos would be suitable to practice vitrification and (2) to analyze the factors that contributed to improving our "learning curve". MATERIALS AND METHODS: 58 expanded blastocysts cultured from commercially available frozen 1-cell mouse embryos (B6D2F1 x B6C3F1) were used. Embryos were vitrified, during 2 separate attempts, in a closed device (Cryopette) and vitrified and warmed using Ethylene Glycol-cryoprotectant vitrification kit (Vitrification Attempt 1 and 2 - VA1 and 2; Warming Attempt 1 and 2 - WA1 and 2). Differences in attempts by more focusing on the reaction of the embryo itself. The survival rate (SR) of embryos was evaluated immediately after warming (TO), then rinsed and cultured for 24 hours in an HTF-like medium (Cleavage Medium - Sage; Cooper Surgical; U.S.A.). Additional evaluations were done at 2 and 24 hours of culture (T2 and T24, respectively). RESULTS: The combined SR for both attempts were 70.6, 60.3 and 34.4% at TO, T2 and T24, respectively. Embryo loss was significantly higher in WA1 compared to WA2 (30.8 versus 10.1%; p=.05). The SR at TO after VA1 and VA2 were similar (90.9 versus 80.9%) and the SR after VA1+WA1 versus VA1+WA2 was 55.6 vs. 76.9% at T2 and 22.2 vs. 61.5% at T24, respectively (NS). CONCLUSION: Commercially frozen mouse embryos can provide essential information for initiating a Vitrification Program applicable to human embryos and oocytes. Practice is critical, particularly Warming, which can provide the confidence needed to adapt and optimize these protocols before vitrifying limited human tissues or gametes.
- 1 February 2015
- Published by Elsevier in Fertility and Sterility
- Vol. 103 (2) , 469-477
Searching for metastases in ovarian tissue before autotransplantation: a tailor-made approach
- 1 February 2015
- Published by Elsevier in Fertility and Sterility
- Vol. 103 (2) , 469-477
Searching for metastases in ovarian tissue before autotransplantation: a tailor-made approach